Brussels (Belgium), July 6, 2005 - UCB announces that it has signed an agreement with Neogen Corporation (NASDAQ: NEOG) to sell UCB's dairy antibiotic testing business.
These activities represent a small part of UCB's global business and are considered non-core. This divestment is therefore in line with UCB's long-term vision to build a global biopharmaceutical leader bringing to specialists first, new medicines to treat patients suffering from severe diseases.
For the pdf-version of this press release, please click on the link below:
